Clinical Trial Update: Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101 [Phase 3]

View source ↗

Summary

Long-term follow-up study evaluating safety and maintenance of efficacy for ATX-101 (Phase 3) has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Submental Fat

Drugs mentioned

• ATX-101 (Deoxycholic acid)

Snippet

Sponsor: Kythera Biopharmaceuticals | Conditions: Submental Fat, Healthy | Phase 3 | Status: COMPLETED | Results posted: 2020-02-17